Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)
Sponsor: ITB-Med LLC
Summary
The purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in living donor renal transplant recipients
Official title: A Safety and Tolerability Study of TCD601 (Siplizumab), a Human Anti-CD2 Antibody, Combined With Donor Bone Marrow Cell Infusion and Non-Myeloablative Conditioning, Including Fludarabine and Cyclophosphamide, for Tolerance Induction in Living Donor Renal Transplantation
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2022-12-14
Completion Date
2030-03
Last Updated
2026-02-06
Healthy Volunteers
No
Conditions
Interventions
TCD601
Investigational Product
Locations (3)
Massachusetts General Hospital
Boston, Massachusetts, United States
Mayo Clinic
Rochester, Minnesota, United States
Samsung Medical University
Seoul, South Korea